Home » Newsletters » BioWorld Science

BioWorld Science

April 11, 2017

View Archived Issues

INCB-062079 shows potent and selective inhibition in models of FGF19-FGFR4-dependent cancers

Leptin receptor antagonist allo-aca reverses leptin-induced aggressive prostate cancer phenotype

BGS-649 normalizes testosterone levels in patients with secondary hypogonadotropic hypogonadism

Phase II YOSEMITE trial of demcizumab in pancreatic cancer does not meet primary endpoint

Bayer terminates its option to license vantictumab or ipafricept from OncoMed

Alzheimer's disease treatment candidate Q-134R inhibits NFATsignaling

Pfizer presents allosteric inhibitors of IL-2-inducible T-cell kinase for inflammatory diseases

Ovid Therapeutics starts phase I trial of gaboxadol in Angelman syndrome

FDA accepts Syros Pharmaceuticals's IND for SY-1365

FORMA Therapeutics meets two more objectives in Celgene collaboration

TherapeuticsMD gives update on TX-004HR NDA

Roche reports that phase III ALEX study of alectinib met its PFS endpoint

Redx Pharma patents tyrosine-protein kinase BTK inhibitors

GlaxoSmithKline divulges novel bromodomain and extra-terminal protein inhibitors

Pfizer discovers new beta-secretase 1 inhibitors

Janssen Pharmaceutica discloses novel fibroblast growth factor receptor inhibitors

Roche synthesizes novel E-NPP 2/CA-II inhibitors

CN Bio Innovations gains worldwide rights to hepatitis B program from Bristol-Myers Squibb

FDA sets PDUFA date for Zerviate NDA

Nippon Kayaku submits application for marketing approval of CT-P6 in Japan

FDA clears way for pilot trial of Cytori Cell Therapy in thermal burn injury

Ferring and Alrise Biosystems enter exclusive agreement

eFFECTOR Therapeutics selects Cancer Genetics to provide biomarker services for lead candidate

Geron provides update on data reviews of imetelstat trials

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...